Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Krolewiecki
  NCT004381884		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
30/15 inconclusive
    NCT04523831 (Mahmud)
          NCT04523831    		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    		200/200 safety concern
    • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    Shahbaznejad
          IRCT20111224008507N3    		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    		35/38 inconclusive
      4 studies excluded by filtering options (2 RCT / 2 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons